Mycophenolate Mofetil Teva

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Teva, is an immunosuppressant presented as an oral formulation for oral use. It belongs to the antimetabolite class and is employed to prevent organ transplant rejection and to treat lupus nephritis in adult patients.

GNH USA supplies Mycophenolate Mofetil Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology units and pharmacies worldwide, with support for regulatory and logistics requirements and ensuring timely delivery to meet patient needs.

Mycophenolate Mofetil is an antimetabolite immunosuppressant used in conditions requiring inhibition of the immune response.

- Organ transplant rejection: prevents acute and chronic rejection in kidney, heart and liver transplants. - Lupus nephritis: reduces proteinuria and preserves renal function in systemic lupus erythematosus affecting the kidneys. - Graft‑versus‑host disease prophylaxis: used as part of combination therapy to reduce incidence of GVHD after hematopoietic stem cell transplantation.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient head pain. - Upper respiratory infections: mild colds or sinusitis.

Serious or Rare Side Effects: - Neutropenia: dangerously low white blood cell count. - Anemia: reduced red blood cell production. - Lymphopenia: decreased lymphocyte numbers. - Severe infections: opportunistic bacterial, viral or fungal infections. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy risk: increased incidence of certain cancers with long‑term use.

When prescribing Mycophenolate Mofetil, clinicians should consider several safety measures.

- Monitor blood counts: regular CBC to detect cytopenias. - Assess renal function: adjust dose if impaired. - Screen for infections: evaluate for opportunistic infections before and during therapy. - Avoid pregnancy: drug may be teratogenic; use effective contraception. - Store at ambient temperature: keep below 25°C, protect from moisture and light in original container.

Mycophenolate Mofetil interacts with several medicines that may alter its efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: increased mycophenolate exposure, monitor levels. - Tacrolimus: may increase risk of nephrotoxicity. - Antacids containing aluminum or magnesium: reduce absorption, separate dosing.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone marrow suppression. - Live vaccines: reduced efficacy, avoid administration. - Rifampin: may decrease mycophenolate plasma concentrations.